Research Priorities for Chagas Disease, Human African Trypanosomiasis and Leishmaniasis
TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis
Technical Report Series, No 975
World Health Organization
ISBN-13    9789241209755 ISBN-10    9241209755
Order Number    11000975 Format    Package
Price    CHF    40.00 / US$    48.00 Developing countries:    CHF    28.00
English     2012        112   pages
Summary
Table of contents
Related Publications
Translation(s) available
 
   Add to your order
 
 
Table of contents
Abbreviations and acronyms
Executive summary
1. Introduction
1.1 Reasons for setting research priorities
1.2 TDR stewardship mandate
1.3 Goal of this report /strategic objectives
1.4 Overview
2. Methodology and prioritization
2.1 Authoritative evidence review to define thematic areas
2.2 Stakeholders consultation and second round of criteria-based ranking
2.3 Final round of ranking
3. Epidemiology and burden of disease
3.1 Chagas disease
3.2 Human African trypanosomiasi
3.3 Leishmaniasis
4. Clinical forms, pathogenesis and HIV coinfection
4.1 Chagas disease
4.1.1 Clinical presentations
4.1.2 Chagas heart disease
4.1.3 Gastrointestinal manifestations
4.1.4 Congenital Chagas disease
4.1.5 Chagas disease and HIV coinfection
4.2 Human African trypanosomiasis
4.2.1 Pathogenesis
4.2.2 Clinical presentation
4.3 Leishmaniasis
4.3.1 Clinical presentations
5. Diagnosis
5.1 Chagas disease
5.1.1 Parasitological diagnosis
5.1.2 Serology
5.1.3 Quantitative and qualitative detection of parasite DNA
5.1.4 Diagnosis in newborns
5.1.5 Diagnosis of therapy efficacy and cure
5.1.6 Diagnosis of drug resistant Chagas disease
5.2 Human African trypanosomiasis
5.2.1 Demonstration of parasite
5.2.2 Serology
5.2.3 Quantitative and qualitative detection of parasite DNA
5.2.4 Staging of the disease
5.3 Leishmaniasis
5.3.1 Parasitological diagnosis
5.3.2 Serology
5.3.3 Detection of parasite products
5.3.4 Quantitative and qualitative detection of parasite DNA
6. Drugs and drug resistance
6.1 Current treatment and development of new drugs
6.1.1 Chagas disease
6.1.2 Human African trypanosomiasis
6.1.3 Leishmaniasis
7. Vaccines against Chagas disease, Human African trypanosomiasis and leishmaniasis
7.1 Overview
7.2 Chagas disease
7.3 Human African trypanosomiasis
7.4 Leishmaniasis
8. Vector Control
8.1 Chagas disease: triatomine bug control
8.2 Human African trypanosomiasis: tsetse fly control
8.2.1 Tsetse species of highest priority
8.2.2 Control activities at all levels
8.2.3 Costs of vector control
8.3 Leishmaniasis: sandfly control
8.3.1 Source reduction
8.3.2 Targeting sugar-feeding adult sandflies
8.3.3 Extermination of sandflies feeding on domestic animals
8.3.4 Flight barriers for preventing sandflies from reaching houses
8.3.5 Protection of homes - indoor residual insecticide spraying
8.3.6 Protection of rooms/porches - insecticide diffusers and coils
8.3.7 Personal protection - insecticide-treated nets and repellents
8.3.8 Integrated disease-control campaigns
9. Economic evaluation of health-care interventions
10. Research priority recommendations
Acknowledgements
References
Appendices